THE WHAT? Revlon has reported its results for the quarter ended September 30, 2021. The US beauty manufacturer delivered net sales of US$521.1 million in Q3 2021, a 9.2 percent rise on the prior year period. All reporting segments recorded revenue growth.
THE DETAILS Operating income stood at US$34.1 million, a considerable improvement on Q3 2020’s US$9.7 million loss, which Revlon attributed to high net sales as well as a gross margin improvement.
As reported net loss was US$53.1 million, versus US$44.5 million net loss in the prior-year period, put down to the early extinguishment of debt in 2020 as well as unfavorable variance in foreign currency yoy.
In terms of segments, Elizabeth Arden was the star performer with sales up 15.5 percent yoy, followed by the company’s Portfolio unit (which comprises its Almay, Cutex and Mitchum brands, among others) where sales rose 13.2 percent. Fragrances put on a respectable 7.2 percent while Revlon inched up 4.2 percent.
THE WHY? Debra Perelman, Revlon’s President and Chief Executive Officer, stated, “Our results this quarter demonstrate that our strategy is working. The top-line growth in our brands and strong EBITDA performance are evidence of the sustained positive momentum we are seeing in our business as we continue to execute. For the second consecutive quarter, all our reporting segments increased revenue compared to the prior year, and our e-commerce segment posted double-digit growth. We are also well into the implementation phase of our Revlon Global Growth Accelerator program, which was put in place to support our long-term profitable growth.
“In terms of the macro environment, we continue to navigate global supply chain pressures, including increased prices on key ingredients and components, logistics challenges across all modes of transportation, and persistent labor shortages. As touched on last quarter, we are taking the appropriate steps to address these issues, including aggressively managing costs and implementing select price increases. While we expect these challenges to persist well into 2022, we are prepared to dynamically manage our business until the situation stabilizes.”
Aesthetic medicine products are developed and regulated to meet stringent safety and efficacy standards. They are typically administered by trained healthcare professionals such as dermatologists, plastic surgeons, and specialized nurses in clinical settings. These products aim to provide effective solutions for cosmetic enhancement, skin rejuvenation, and overall aesthetic improvement, contributing to both physical appearance and self-confidence.
Key categories of aesthetic medicine products include:
-
Injectables: This category includes products such as dermal fillers, botulinum toxins (e.g., Botox), and collagen stimulators. These injectables are used to smooth wrinkles, add volume, and improve facial contours.
-
Skin Rejuvenation Treatments: Products like chemical peels, microdermabrasion systems, and laser devices are used to improve skin texture, reduce pigmentation irregularities, and enhance overall skin tone.
-
Skincare Products: These include medical-grade cleansers, moisturizers, serums, and topical treatments containing active ingredients like retinoids, antioxidants, and growth factors. They are formulated to address specific skin concerns such as acne, aging, and hyperpigmentation.
-
Hair Restoration Products: Medical treatments and products designed to promote hair growth and treat conditions such as male and female pattern baldness.
-
Body Contouring and Fat Reduction: Devices and products used for non-surgical body sculpting, such as cryolipolysis (cool sculpting) devices and injectable lipolytics.
-
Cosmeceuticals: High-performance skincare products that bridge the gap between cosmetics and pharmaceuticals, often containing potent ingredients with proven clinical benefits.
-
Wound Care and Scar Management: Products like silicone sheets, gels, and advanced wound dressings used to improve healing and reduce the appearance of scars.
